Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoradiation with or without Atezolizumab in Limited Stage Small Cell Lung Cancer
NCT03811002Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2019
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in small cell lung cancer (SCLC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Survival. Started Jul 2019; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03811002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03811002.